Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 247 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Human Papillomavirus Vaccine Clear all
Completed Not applicable Interventional

HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3

NCT02558803
View directory record Official record
Conditions
Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6, Cervical Cancer, Genital Warts, Oropharyngeal Cancer
Interventions
Simple Reminder
Behavioral
Lead sponsor
Regenstrief Institute, Inc.
Other
Eligibility
11 Years to 17 Years
Enrollment
1,305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

NCT01492582
View directory record Official record
Conditions
Cancer Survivor, Prevention of Human Papillomavirus Infection
Interventions
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58), laboratory biomarker analysis, survey administration, medical chart review
Biological · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
9 Years to 26 Years
Enrollment
1,499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
5
States / cities
Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Making Effective Human Papillomavirus (HPV) Vaccine Recommendations

NCT02377843
View directory record Official record
Conditions
Human Papillomavirus
Interventions
Participatory, Efficient
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

NCT04646005
View directory record Official record
Conditions
Cervical Cancer
Interventions
Cemiplimab, ISA101b
Drug · Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Tucson, Arizona • Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 2 Interventional

SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells

NCT00091130
View directory record Official record
Conditions
Atypical Squamous Cells of Undetermined Significance, Cervical Cancer, High-grade Squamous Intraepithelial Lesion, Low-grade Squamous Intraepithelial Lesion
Interventions
HspE7, placebo, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 2, 2026, 3:23 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Intradermal, Fractional Dose of HPV Vaccines:

NCT04235257
View directory record Official record
Conditions
HPV Infection, HPV Vaccine
Interventions
HPV vaccine
Biological
Lead sponsor
University of Washington
Other
Eligibility
27 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 2, 2026, 3:23 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

NCT03036930
View directory record Official record
Conditions
Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
Interventions
Biospecimen Collection, HPV Self-Collection, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 49 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 2, 2026, 3:23 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers

NCT01087164
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Compliance, Message sidedness
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
11 Years to 15 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 2, 2026, 3:23 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities

NCT00501189
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
human papillomavirus vaccine L1, type 6,11,16,18
Biological
Lead sponsor
Eisenhower Army Medical Center
Federal
Eligibility
18 Years to 26 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Fort Gordon, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 2, 2026, 3:23 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Parents' HPV Stories

NCT06704308
View directory record Official record
Conditions
HPV Vaccination
Interventions
Web Application, Provider Elaborated Prompts
Behavioral
Lead sponsor
Anne E Ray
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 2 Interventional

Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC

NCT04260126
View directory record Official record
Conditions
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
Interventions
Pembrolizumab (KEYTRUDA®) and PDS0101
Combination Product
Lead sponsor
PDS Biotechnology Corp.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
18
States / cities
Greenbrae, California • San Francisco, California • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 2, 2026, 3:23 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Empowering Vietnamese Americans

NCT07164391
View directory record Official record
Conditions
HPV Vaccination, Cancer Prevention
Interventions
Digital Intervention for Vietnamese-American Storytelling (VIDAS), Teen General Health
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Not applicable Interventional Results available

Immunogenicity to Human Papillomavirus Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy

NCT00727636
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Gardasil vaccine
Biological
Lead sponsor
Boston Children's Hospital
Other
Eligibility
9 Years to 26 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2011 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Not applicable Interventional

Normalizing HPV Vaccination in Preteens With a Serious Video Game

NCT04627298
View directory record Official record
Conditions
Human Papillomavirus
Interventions
educational video game for preteens to support HPV vaccination
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
11 Years to 12 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention

NCT03346915
View directory record Official record
Conditions
Human Papilloma Virus, Cervical Cancer, Human Papillomavirus Infection, Oropharyngeal Cancer, Vaginal Cancer, Vulvar Cancer, Anal Cancer, Penile Cancer
Interventions
WoW and BNI
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
9 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Human Papillomavirus (HPV) Vaccination Acceptance by African-American Parents: Identifying Psychosocial Barriers

NCT00680147
View directory record Official record
Conditions
HPV
Interventions
brief informational intervention to promote HPV vaccine acceptance
Behavioral
Lead sponsor
Syracuse University
Other
Eligibility
11 Years and older
Enrollment
614 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 2, 2026, 3:23 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

NCT05232851
View directory record Official record
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography, FDG-Positron Emission Tomography, Biospecimen Collection, Biopsy
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis

NCT00573651
View directory record Official record
Conditions
Arthritis
Interventions
Blood Draws for Serum Titers
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
9 Years to 26 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
4
States / cities
Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing HPV Vaccination in Community-Based Pediatric Practices

NCT03399396
View directory record Official record
Conditions
HPV Vaccines
Interventions
Practice facilitation for HPV vaccine
Behavioral
Lead sponsor
Pamela Hull
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 2, 2026, 3:23 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effectiveness of an eHealth Intervention for Uptake of Cervical Cancer Screening in Hispanic Women

NCT06741241
View directory record Official record
Conditions
Cervical Cancer Screening
Interventions
eHealth Promotora, eHealth Healthy Nutrition
Behavioral
Lead sponsor
Florida A&M University
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 2, 2026, 3:23 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study

NCT01133509
View directory record Official record
Conditions
Genital Human Papilloma Virus Infection
Interventions
Gardasil
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 2, 2026, 3:23 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

NCT04534205
View directory record Official record
Conditions
Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Interventions
BNT113, Pembrolizumab
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Usability of HPV Vaccine Reminders

NCT03987490
View directory record Official record
Conditions
Human Papilloma Virus (HPV)
Interventions
Text Message, PostCard, Standard of Care, Motivational Interview
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
325 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Oct 2, 2026, 3:23 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis*

NCT07339163
View directory record Official record
Conditions
Recurrent Respiratory Papillomatosis (RRP)
Interventions
GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
Biological
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 2, 2026, 3:23 PM EDT